MaxCyte, Inc. (NASDAQ:MXCT) Given Average Recommendation of “Hold” by Analysts

MaxCyte, Inc. (NASDAQ:MXCT) has received an average recommendation of “Hold” from the five research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $7.00.

MXCT has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th.

MaxCyte Price Performance

MXCT opened at $0.81 on Monday. The firm has a 50 day simple moving average of $1.13 and a 200 day simple moving average of $1.40. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $3.58. The company has a market cap of $86.54 million, a price-to-earnings ratio of -1.84 and a beta of 1.22.

Institutional Trading of MaxCyte

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC boosted its position in shares of MaxCyte by 92.7% during the second quarter. CWM LLC now owns 12,132 shares of the company’s stock worth $26,000 after purchasing an additional 5,836 shares in the last quarter. Prudential Financial Inc. acquired a new stake in MaxCyte during the 2nd quarter worth $26,000. State of Wyoming bought a new position in MaxCyte during the second quarter worth about $38,000. Dynamic Technology Lab Private Ltd acquired a new position in MaxCyte in the second quarter valued at about $40,000. Finally, Kwmg LLC grew its stake in MaxCyte by 75.8% in the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after acquiring an additional 11,135 shares during the period. 68.81% of the stock is owned by institutional investors.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.